New hope for tough lung cancers: targeted drug shows promise

NCT ID NCT04940325

First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 22 times

Summary

This study tests a new drug called DS-1062a in about 100 people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. Participants must have already tried at least one but no more than three standard treatments. The drug is given every three weeks and aims to shrink tumors while researchers check for side effects and look at biomarkers to understand who benefits most.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Hospitalier Intercommunal de Créteil

    Créteil, 94010, France

  • Gustave Roussy

    Villejuif, 94805, France

  • Hospices Civils de Lyon - Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69310, France

  • Hôpital Cochin

    Paris, 75014, France

  • Hôpital Tenon

    Paris, 75970, France

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67091, France

  • Institut Bergonié

    Bordeaux, 33076, France

  • Institut de Cancérologie, CHRU Morvan de Brest

    Brest, 29200, France

Conditions

Explore the condition pages connected to this study.